• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Professional Introduction to Compound with CAS No. 1353985-78-0 and Product Name: 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol

The compound with the CAS number 1353985-78-0 and the product name 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique structural and chemical properties, has garnered considerable attention in recent years due to its potential applications in drug development and therapeutic interventions. The molecular structure of this compound incorporates a combination of functional groups that make it a versatile intermediate in synthetic chemistry, particularly in the synthesis of more complex molecules.

In recent years, there has been a growing interest in the development of novel pharmacological agents that target specific biological pathways with high selectivity and efficacy. The compound 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol fits into this category, as its molecular framework suggests potential interactions with various biological targets. Specifically, the presence of the ethyl-(1-methyl-piperidin-4-yl)-amino moiety indicates that this compound may exhibit properties conducive to binding to enzymes or receptors involved in critical metabolic and signaling pathways.

One of the most compelling aspects of this compound is its structural similarity to known bioactive molecules. The piperidine ring, a common structural motif in many pharmaceuticals, is known for its ability to enhance binding affinity and metabolic stability. The substitution of the piperidine ring with an ethyl group further modulates its pharmacokinetic properties, making it an attractive candidate for further exploration in drug discovery. Additionally, the presence of an amino group provides a site for further functionalization, allowing chemists to tailor the compound’s properties for specific applications.

Recent studies have highlighted the importance of understanding the three-dimensional structure of molecules in predicting their biological activity. Computational modeling techniques have been increasingly employed to simulate the interactions between this compound and potential target proteins. These studies suggest that 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol may exhibit inhibitory effects on certain enzymes implicated in diseases such as cancer and inflammatory disorders. The precise mechanism of action remains under investigation, but preliminary findings are promising.

The synthesis of 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic methodologies, including catalytic hydrogenation and nucleophilic substitution reactions, have been employed to construct the desired molecular framework. The use of chiral auxiliaries or asymmetric catalysts may be necessary to achieve enantiopure forms of the compound, which are often essential for pharmaceutical applications.

In addition to its potential as a lead compound in drug discovery, 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol has shown promise as a building block for more complex molecules. Its structural features make it amenable to further derivatization, allowing researchers to explore a wide range of pharmacological profiles. For instance, modifications at the amino group or the piperidine ring could lead to compounds with enhanced solubility, bioavailability, or target specificity.

The safety and efficacy of any pharmaceutical compound must be thoroughly evaluated before it can be considered for clinical use. Preclinical studies involving cell culture assays and animal models have been conducted to assess the potential toxicity and pharmacological effects of 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol. These studies have provided valuable insights into its biological behavior and have helped identify potential dosing regimens and safety margins.

One area where this compound shows particular promise is in the treatment of neurological disorders. Piperidine derivatives are known to interact with neurotransmitter systems, making them candidates for drugs targeting conditions such as depression, anxiety, and neurodegenerative diseases. The specific modifications present in 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol may confer unique advantages over existing treatments by offering improved selectivity or reduced side effects.

As research continues to uncover new therapeutic targets and mechanisms, compounds like 2-[Ethyl-(1-methyl-piperidin-4-yl)-amino]-ethanol will play an increasingly important role in drug development. The ability to design molecules with precise structural features allows researchers to fine-tune their pharmacological properties, leading to more effective treatments for a variety of diseases.

The future prospects for this compound are bright, with ongoing research focused on optimizing its synthesis, exploring new applications, and evaluating its clinical potential. Collaborative efforts between synthetic chemists, medicinal chemists, and biologists will be crucial in translating laboratory findings into tangible therapeutic benefits for patients worldwide.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)